Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Revenue (2016 - 2025)

Historic Revenue for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to $756217.0.

  • China Pharma Holdings' Revenue fell 3126.25% to $756217.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year decrease of 2691.54%. This contributed to the annual value of $4.5 million for FY2024, which is 3540.53% down from last year.
  • According to the latest figures from Q3 2025, China Pharma Holdings' Revenue is $756217.0, which was down 3126.25% from $1.0 million recorded in Q2 2025.
  • China Pharma Holdings' Revenue's 5-year high stood at $2.9 million during Q4 2022, with a 5-year trough of $756217.0 in Q3 2025.
  • For the 5-year period, China Pharma Holdings' Revenue averaged around $1.7 million, with its median value being $1.6 million (2022).
  • In the last 5 years, China Pharma Holdings' Revenue skyrocketed by 3369.79% in 2021 and then tumbled by 4724.83% in 2024.
  • Over the past 5 years, China Pharma Holdings' Revenue (Quarter) stood at $2.9 million in 2021, then grew by 1.09% to $2.9 million in 2022, then dropped by 26.41% to $2.1 million in 2023, then crashed by 47.25% to $1.1 million in 2024, then crashed by 33.31% to $756217.0 in 2025.
  • Its Revenue was $756217.0 in Q3 2025, compared to $1.0 million in Q2 2025 and $1.1 million in Q1 2025.